Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lubiprostone in NAFLD
NCT05768334Phase 3Completed
- Sponsor
- Helwan University
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of cobiprostone in non-alcoholic fatty liver disease (NAFLD), sponsored by Helwan University. Started Nov 2020; status: completed.
02
Drugs
cobiprostone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05768334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768334.